Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will it Really be a Breakthrough?
Michał Ciebiera(Postgraduate School of Molecular Medicine), Grzegorz Jakiel(Postgraduate School of Molecular Medicine), Antoni Sierant(Postgraduate School of Molecular Medicine), Simone Ferrero(Ospedale Policlinico San Martino), Fabio Barra(Institute for Health Metrics and Evaluation), Antonio Simone Laganà(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Salvatore Giovanni Vitale(University of Cagliari), Salvatore Caruso(University of Catania), George A. Vilos(Western University), Antonio Cianci(Agostino Gemelli University Polyclinic)
Cited by 21
Related Papers
ESHRE guideline: endometriosis
|Human Reproduction Open|2022|1.5k
Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group
|Ultrasound in Obstetrics and Gynecology|2016|882
The Management of Uterine Leiomyomas
|Journal of Obstetrics and Gynaecology Canada|2015|625
The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis
|The Lancet Public Health|2022|373
Bowel Endometriosis: Presentation, Diagnosis, and Treatment
|Obstetrical & Gynecological Survey|2007|333